By targeting the tumor angiogenesis marker CD105, HMSN showed a tumor uptake of up to 10%ID/g in vivo, more than three times higher than that of the untargeted group, and its anticancer drug loading capacity was 3–15 times higher than that of conventional mesoporous silica nanoparticles, providing a new nanoplatform for accurate cancer diagnosis and treatment [64]. This evidence concerns the gene ENG and neoplasm.